Vanguard Group
ABEO icon

Vanguard Group’s Abeona Therapeutics ABEO Stock Holding History

Vanguard Group’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$14.5M Buy
2,757,143
+154,242
+6% +$776K ﹤0.01% 2769
2025
Q3 		$13.7M Buy
2,602,901
+95,878
+4% +$608K ﹤0.01% 2807
2025
Q2 		$14.2M Buy
2,507,023
+486,838
+24% +$2.77M ﹤0.01% 2721
2025
Q1 		$9.62M Buy
2,020,185
+54,162
+3% +$295K ﹤0.01% 2863
2024
Q4 		$11M Sell
1,966,023
-41,603
-2% -$256K ﹤0.01% 2904
2024
Q3 		$12.7M Buy
2,007,626
+54,125
+3% +$283K ﹤0.01% 2840
2024
Q2 		$8.28M Buy
1,953,501
+851,543
+77% +$4.34M ﹤0.01% 3027
2024
Q1 		$7.99M Buy
1,101,958
+827
+0.1% +$5.24K ﹤0.01% 3089
2023
Q4 		$5.52M Buy
1,101,131
+348,196
+46% +$1.53M ﹤0.01% 3246
2023
Q3 		$3.17M Buy
752,935
+83,332
+12% +$315K ﹤0.01% 3434
2023
Q2 		$2.7M Buy
669,603
+211,262
+46% +$739K ﹤0.01% 3567
2023
Q1 		$1.29M Buy
458,341
+165,811
+57% +$433K ﹤0.01% 3836
2022
Q4 		$901K Buy
292,530
+84
+0% +$314 ﹤0.01% 3943
2022
Q3 		$889K Buy
292,446
+201,619
+222% +$832K ﹤0.01% 4041
2022
Q2 		$472K Buy
90,827
+1,576
+2% +$7.97K ﹤0.01% 4310
2022
Q1 		$703K Sell
89,251
-57,209
-39% -$393K ﹤0.01% 4306
2021
Q4 		$1.23M Sell
146,460
-3,439
-2% -$63.2K ﹤0.01% 4204
2021
Q3 		$4.2M Buy
149,899
+798
+0.5% +$25.6K ﹤0.01% 3769
2021
Q2 		$5.82M Buy
149,101
+9,289
+7% +$379K ﹤0.01% 3516
2021
Q1 		$6.57M Buy
139,812
+12,653
+10% +$697K ﹤0.01% 3385
2020
Q4 		$4.99M Buy
127,159
+3,429
+3% +$117K ﹤0.01% 3352
2020
Q3 		$3.15M Buy
123,730
+3,475
+3% +$219K ﹤0.01% 3344
2020
Q2 		$8.76M Buy
120,255
+3,395
+3% +$235K ﹤0.01% 2842
2020
Q1 		$6.13M Buy
116,860
+11,340
+11% +$757K ﹤0.01% 2867
2019
Q4 		$8.63M Buy
105,520
+35,922
+52% +$2.53M ﹤0.01% 2929
2019
Q3 		$3.93M Sell
69,598
-3,550
-5% -$266K ﹤0.01% 3223
2019
Q2 		$8.74M Buy
73,148
+7,745
+12% +$1.3M ﹤0.01% 2936
2019
Q1 		$12M Buy
65,403
+16,524
+34% +$2.95M ﹤0.01% 2731
2018
Q4 		$8.72M Sell
48,879
-12,681
-21% -$2.77M ﹤0.01% 2833
2018
Q3 		$19.7M Buy
61,560
+4,333
+8% +$1.54M ﹤0.01% 2583
2018
Q2 		$22.9M Buy
57,227
+1,971
+4% +$861K ﹤0.01% 2511
2018
Q1 		$19.8M Buy
55,256
+2,854
+5% +$1.06M ﹤0.01% 2502
2017
Q4 		$20.8M Buy
52,402
+11,727
+29% +$4.85M ﹤0.01% 2468
2017
Q3 		$17.3M Sell
40,675
-2,592
-6% -$697K ﹤0.01% 2546
2017
Q2 		$6.92M Buy
43,267
+4,349
+11% +$593K ﹤0.01% 2950
2017
Q1 		$4.86M Buy
38,918
+2,399
+7% +$309K ﹤0.01% 3060
2016
Q4 		$4.43M Buy
36,519
+13,828
+61% +$2.17M ﹤0.01% 3106
2016
Q3 		$3.4M Buy
22,691
+1,079
+5% +$106K ﹤0.01% 3176
2016
Q2 		$1.27M Sell
21,612
-847
-4% -$57.9K ﹤0.01% 3534
2016
Q1 		$1.44M Buy
22,459
+1,083
+5% +$71.7K ﹤0.01% 3488
2015
Q4 		$1.8M Buy
21,376
+1,657
+8% +$166K ﹤0.01% 3432
2015
Q3 		$2M Buy
19,719
+10,138
+106% +$1.35M ﹤0.01% 3377
2015
Q2 		$1.21M Buy
+9,581
New +$1.44M ﹤0.01% 3604

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $911M AUM 45.9% 1-Year Est. Return

Vanguard Group's ABEO Position: Q4 2025 in Review

Vanguard Group increased its Abeona Therapeutics (ABEO) stake by 5.9% in Q4 2025, buying an estimated $776K and bringing the position to 2,757,143 shares worth $14.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2769.

Vanguard Group first reported a position in ABEO in Q2 2015 and has held it in 43 quarters since. The position peaked at $22.9M in Q2 2018. 104 funds tracked by Wall St. Rank hold ABEO as of Q4 2025.

  • Vanguard Group held 2,757,143 shares of Abeona Therapeutics worth $14.5M as of Q4 2025.
  • Vanguard Group bought 154,242 Abeona Therapeutics shares in Q4 2025, an estimated $776K.
  • Abeona Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2769 holding.
  • Vanguard Group first reported a position in Abeona Therapeutics in Q2 2015 and has held it in 43 quarters since.
  • Vanguard Group's Abeona Therapeutics position peaked at $22.9M in Q2 2018.
  • 104 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.